TABLE 5.

Logistic Regression Results Predicting High Adherence

	3 Months			6 Months			9 Months
	OR	95% CL		OR	95% CL		OR	95% CL
PDC ≥ 0.80 to index NOAC
Dabigatran vs. rivaroxaban	0.60	0.53	0.70	0.66	0.57	0.77	0.72	0.60	0.87
Dabigatran vs. apixaban	0.73	0.69	0.79	0.75	0.69	0.83	0.70	0.57	0.87
Apixaban vs. rivaroxaban	0.82	0.67	1.01	0.88	0.69	1.12	1.03	0.69	1.53
Age 65-74 vs. age < 65	1.78	1.52	2.09	1.51	1.28	1.78	1.52	1.23	1.89
Age ≥ 75 vs. age < 65	1.76	1.51	2.05	1.84	1.56	2.17	1.81	1.46	2.26
Hypertension	1.19	1.05	1.36	1.20	1.05	1.38	1.31	1.09	1.57
Diabetes	1.32	1.08	1.62	1.53	1.24	1.90	1.46	1.11	1.92
PDC ≥0.80 to all OAC
Dabigatran vs. rivaroxaban	0.75	0.65	0.87	0.81	0.70	0.95	0.85	0.70	1.03
Dabigatran vs. apixaban	0.88	0.82	0.94	0.93	0.86	1.03	0.94	0.90	1.15
Apixaban vs. rivaroxaban	0.85	0.69	1.06	0.87	0.68	1.11	0.90	0.61	1.35
Age 65-74 vs. age < 65	1.98	1.68	2.34	1.68	1.41	1.99	1.65	1.33	2.05
Age ≥ 75 vs. age < 65	1.92	1.63	2.26	1.92	1.62	2.27	1.93	1.55	2.40
Hypertension	1.20	1.05	1.38	1.18	1.03	1.37	1.32	1.10	1.59
Diabetes	1.31	1.06	1.62	1.48	1.18	1.85	1.32	1.00	1.75

Note: Other variables included in the model with nonsignificant effects: gender, urbal/rural status, region, Charlson comorbidity score, history of stroke, vascular disease, renal disease, liver disease, prior bleeding or medications that increase risk of bleeding, alcohol abuse, hyperlipidemia, cancer ± metastases, and dementia. Bold results are significant at P < 0.05.

CL = confidence limit; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulant; OR = odds ratio; PDC = proportion of days covered.